GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » The Spectranetics Corp (NAS:SPNC) » Definitions » Altman Z-Score

The Spectranetics (The Spectranetics) Altman Z-Score : 2.07 (As of Apr. 26, 2024)


View and export this data going back to 1992. Start your Free Trial

What is The Spectranetics Altman Z-Score?

The Altman Z-Score is a model designed to predict the likelihood of a company going bankrupt within the next two years. Created by American finance professor Edward Altman in 1968, the model is specifically designed for publicly traded manufacturing companies with assets greater than $1 million.

The Spectranetics has a Altman Z-Score of 2.07, indicating it is in Grey Zones. This implies that The Spectranetics is in some kind of financial stress. If it is below 1.81, the company may face bankrupcy risk.

The zones of discrimination were as such:

When Altman Z-Score <= 1.8, it is in Distress Zones.
When Altman Z-Score >= 3, it is in Safe Zones.
When Altman Z-Score is between 1.8 and 3, it is in Grey Zones.

The historical rank and industry rank for The Spectranetics's Altman Z-Score or its related term are showing as below:


The Spectranetics Altman Z-Score Historical Data

The historical data trend for The Spectranetics's Altman Z-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

The Spectranetics Altman Z-Score Chart

The Spectranetics Annual Data
Trend Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16
Altman Z-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 14.71 23.70 3.06 0.93 1.45

The Spectranetics Quarterly Data
Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17
Altman Z-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.12 1.57 1.45 1.71 2.05

Competitive Comparison of The Spectranetics's Altman Z-Score

For the Medical Devices subindustry, The Spectranetics's Altman Z-Score, along with its competitors' market caps and Altman Z-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


The Spectranetics's Altman Z-Score Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, The Spectranetics's Altman Z-Score distribution charts can be found below:

* The bar in red indicates where The Spectranetics's Altman Z-Score falls into.



The Spectranetics Altman Z-Score Calculation

Altman Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.

The Spectranetics's Altman Z-Score for today is calculated with this formula:

Z=1.2*X1+1.4*X2+3.3*X3+0.6*X4+1.0*X5
=1.2*0.1571+1.4*-0.6827+3.3*-0.1254+0.6*4.3185+1.0*0.6567
=2.07

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency. GuruFocus does not calculate Altman Z-Score when X4 or X5 value is 0.

Trailing Twelve Months (TTM) ended in Jun. 2017:
Total Assets was $433.4 Mil.
Total Current Assets was $142.3 Mil.
Total Current Liabilities was $74.2 Mil.
Retained Earnings was $-295.9 Mil.
Pre-Tax Income was -24.236 + -18.275 + -12.311 + -13.18 = $-68.0 Mil.
Interest Expense was -3.598 + -3.409 + -3.337 + -3.322 = $-13.7 Mil.
Revenue was 74.714 + 69.68 + 71.926 + 68.265 = $284.6 Mil.
Market Cap (Today) was $1,693.6 Mil.
Total Liabilities was $392.2 Mil.

* Note that for stock reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data.

X1=Working Capital/Total Assets
=(Total Current Assets - Total Current Liabilities)/Total Assets
=(142.274 - 74.206)/433.353
=0.1571

X2=Retained Earnings/Total Assets
=-295.853/433.353
=-0.6827

X3=Earnings Before Interest and Taxes/Total Assets
=(Pre-Tax Income - Interest Expense)/Total Assets
=(-68.002 - -13.666)/433.353
=-0.1254

X4=Market Value Equity/Book Value of Total Liabilities
=Market Cap/Total Liabilities
=1693.560/392.161
=4.3185

X5=Revenue/Total Assets
=284.585/433.353
=0.6567

The zones of discrimination were as such:

Distress Zones - 1.81 < Grey Zones < 2.99 - Safe Zones

The Spectranetics has a Altman Z-Score of 2.07 indicating it is in Grey Zones.

Study by Altman found that companies that are in Distress Zone have more than 80% of chances of bankruptcy in two years.


The Spectranetics  (NAS:SPNC) Altman Z-Score Explanation

X1: The Working Capital/Total Assets (WC/TA) ratio is a measure of the net liquid assets of the firm relative to the total capitalization. Working capital is defined as the difference between current assets and current liabilities. Ordinarily, a firm experiencing consistent operating losses will have shrinking current assets in relation to total assets. Altman found this one proved to be the most valuable liquidity ratio comparing with the current ratio and the quick ratio. This is however the least significant of the five factors.

X2: Retained Earnings/Total Assets: the RE/TA ratio measures the leverage of a firm. Retained earnings is the account which reports the total amount of reinvested earnings and/or losses of a firm over its entire life. Those firms with high RE, relative to TA, have financed their assets through retention of profits and have not utilized as much debt.

X3, Earnings Before Interest and Taxes/Total Assets (EBIT/TA): This ratio is a measure of the true productivity of the firm's assets, independent of any tax or leverage factors. Since a firm's ultimate existence is based on the earning power of its assets, this ratio appears to be particularly appropriate for studies dealing with corporate failure. This ratio continually outperforms other profitability measures, including cash flow.

X4, Market Value of Equity/Book Value of Total Liabilities (MVE/TL): The measure shows how much the firm's assets can decline in value (measured by market value of equity plus debt) before the liabilities exceed the assets and the firm becomes insolvent.

X5, Revenue/Total Assets (S/TA): The capital-turnover ratio is a standard financial ratio illustrating the sales generating ability of the firm's assets.

Read more about Altman Z-Score and the original research.


Be Aware

Altman Z-Score does not apply to financial companies.


The Spectranetics Altman Z-Score Related Terms

Thank you for viewing the detailed overview of The Spectranetics's Altman Z-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


The Spectranetics (The Spectranetics) Business Description

Traded in Other Exchanges
N/A
Address
Spectranetics manufactures and sells single-use medical devices used in minimally invasive cardiovascular procedures. The firm operates in the three categories: vascular intervention, lead management, and laser, service, and other. The vascular intervention business contributes the majority of revenue and sells laser and aspiration catheters, balloon catheters, and support catheters. The lead management business sells devices used to remove pacemaker and defibrillator cardiac leads. The laser, service, and other business includes a laser system for cardiovascular procedures. Spectranetics generates the vast majority of its revenue in the United States.
Executives
Todd C Schermerhorn director C/O C.R BARD INC, 730 CENTRAL AVE, MURRAY HILL NJ 07974
R John Fletcher director C/O VYANT BIO, INC., 201 ROUTE 17 NORTH, 2ND FLOOR, RUTHERFORD NJ 07070
William C Jennings director 108 CHERRY HILL DRIVE, BEVERLY MA 01915-1053
B Kristine Johnson director 366 FERNDALE RD S, WAYZATA MN 55391
Scott William Drake director, officer: President, CEO 9965 FEDERAL DRIVE, COLORADO SPRINGS CO 80921
Maria Sainz director C/O ORTHOFIX INTERNATIONAL N. V., 3451 PLANO PARKWAY, LEWISVILLE TX 75056
Shahriar Matin officer: Chief Operating Officer 96 TALAMINE COURT, COLORADO SPRINGS CO 80907
Stacy Powell Mcmahan officer: CFO 1000 CRANBERRY WOODS DRIVE, CRANBERRY TOWNSHIP PA 16066
Anne Melissa Dowling director 9965 FEDERAL DRIVE, COLORADO SPRINGS CO 80921
Jonathan Will Mcguire officer: COO 96 TALAMINE COURT, COLORADO SPRINGS CO 80907
Stephen D Okland officer: Vice President of Sales 96 TALAMINE COURT, COLORADO SPRINGS CO 80907
Martin T Hart director 2401 EAST 2ND AVE., SUITE 250, DENVER CO 80206